| Attributes | Values |
|---|
| rdf:type
| |
| rdfs:label
| |
| equivalentClass
| |
| Has_Target
| |
| Concept_In_Subset
| |
| Semantic_Type
| - Organic Chemical
- Pharmacologic Substance
|
| Preferred_Name
| |
| NSC_Code
| |
| UMLS_CUI
| |
| CAS_Registry
| |
| Accepted_Therapeutic_Use_For
| - Aphthous stomatitis; Crohns disease; cutaneous manifestations of erythema nodosum leprosum; GVHD; HIV-associated wasting syndrome; Karposi sarcoma; lepromatous leprosy; multiple myeloma; mycobacterium tuberculosis and nontuberculosis; primary brain tumors
|
| In_Clinical_Trial_For
| - Acute myeloid leukemia; brain metastases; chronic myelogenous leukemia; colorectal cancer; graft versus host related stomatitis; gynecologic sarcomas; hematologic cancer; hepatocellular carcinoma; HIV infections; malignant glioma
- Melanoma; multiple myeloma; myelodysplastic syndromes; Non-Hodgkins lymphoma; non-small cell lung cancer; HIV associated oral lesions; prostate cancer; renal cell carcinoma; small cell lung cancer; unspecified solid tumors
|
| FDA_UNII_Code
| |
| Contributing_Source
| |
| ALT_DEFINITION
| - A drug that is used to treat multiple myeloma in patients who have just been diagnosed, and a painful skin disease related to leprosy. It is also being studied in the treatment of other types of cancer. Thalomid belongs to the family of drugs called angiogenesis inhibitors.NCI-GLOSS
|
| PDQ_Open_Trial_Search_ID
| |
| PDQ_Closed_Trial_Search_ID
| |
| Chemical_Formula
| |
| Legacy_Concept_Name
| |
| CHEBI_ID
| |
| FULL_SYN
| - ThalidomideSYDTPNSC0066847
- 2,6-Dioxo-3-phthalimidopiperidineSNNCI
- N-PhthaloylglutamimideSYNCI
- ThalidomidePTNCI
- 2-(2,6-Dioxo-3-piperidinyl)-1H-isoindole-1,3(2H)-dioneSNNCI
- Sedoval K-17FBNCI
- 2, 6-Dioxo-3-phthalimidopiperidineSYDTPNSC0066847
- thalidomidePTNCI-GLOSSCDR0000045458
- 3-PhthalimidoglutarimideSNNCI
- N-(2,6-Dioxo-3-piperidyl)phthalimideSNNCI
- ThalidomidePTDCP01269
- N-(2,6-Dioxo-3-piperidyl)phthalimideSYDTPNSC0066847
- (+)-ThalidomideSYDTPNSC0091729
- (-)-ThalidomideSYDTPNSC0091730
- KevadonSYDTPNSC0066847
- TalimolSYDTPNSC0066847
- N-Phthalylglutamic acid imideSYDTPNSC0066847
- N-PhthaloylglutamimideSYDTPNSC0066847
- DistavalSYDTPNSC0066847
- SoftenonSYDTPNSC0066847
- Alpha-PhthalimidoglutarimideSYNCI
- .alpha.-PhthalimidoglutarimideSYDTPNSC0066847
- Phthalimide, N-(2, 6-dioxo-3-piperidyl)-, (+)-SYDTPNSC0091729
- Phthalimide, N-(2, 6-dioxo-3-piperidyl)-, (-)-SYDTPNSC0091730
- N-Phthalylglutamic Acid ImideSYNCI
- SedalisFBNCI
- KevadonFBNCI
- TalimolFBNCI
- ConterganSYDTPNSC0066847
- SynovirBRNCI
- ThalomidPTNCI-GLOSSCDR0000507648
- ThalomidBRNCI
- DistavalFBNCI
- SoftenonFBNCI
- THALIDOMIDEPTFDA4Z8R6ORS6L
- PantosedivSYDTPNSC0066847
- ConterganFBNCI
- PantosedivFBNCI
- NeurosedynFBNCI
|
| DEFINITION
| - A synthetic derivative of glutamic acid (alpha-phthalimido-glutarimide) with teratogenic, immunomodulatory, anti-inflammatory and anti-angiogenic properties. Thalidomide acts primarily by inhibiting both the production of tumor necrosis factor alpha (TNF-alpha) in stimulated peripheral monocytes and the activities of interleukins and interferons. This agent also inhibits polymorphonuclear chemotaxis and monocyte phagocytosis. In addition, thalidomide inhibits pro-angiogenic factors such as vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (bFGF), thereby inhibiting angiogenesis.NCI
|
| code
| |
| is someValuesFrom
of | |
![[RDF Data]](/fct/images/sw-rdf-blue.png)
![[cxml]](/fct/images/cxml_doc.png)
![[csv]](/fct/images/csv_doc.png)
![[text]](/fct/images/ntriples_doc.png)
![[turtle]](/fct/images/n3turtle_doc.png)
![[ld+json]](/fct/images/jsonld_doc.png)
![[rdf+json]](/fct/images/json_doc.png)
![[rdf+xml]](/fct/images/xml_doc.png)
![[atom+xml]](/fct/images/atom_doc.png)
![[html]](/fct/images/html_doc.png)